English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

This study examined non-adherence to biological therapy with adalimumab and etanercept and associated factors in patients with rheumatic diseases treated under the Brazilian Unified National Health System in Minas Gerais State, Brazil. A non-concurrent cohort study was performed from pharmacy records of adult patients that had recently initiated treatment. Patient non-adherence was measured by proportion of days covered (PDC), and non-adherent patients were defined as PDC &lt; 0.8. A total of 1,150 patients were included, with the following breakdown: 64.3% rheumatoid arthritis, 8.5% psoriatic arthritis , and 27.2% ankylosing spondylitis. In total, 33.5% of patients were non-adherent. Factors such as younger age (19-39 years), female gender, diagnosis of rheumatoid arthritis , and initial treatment with etanercept were associated with low adherence. The results indicate a high prevalence of non-adherence, which can lead to worse health outcomes and increase healthcare use and costs.

Não adesão à terapia biológica em pacientes com doenças reumáticas no Sistema Único de Saúde em Minas Gerais, Brasil